JC

Moderna’s financial woes continued this week as the stock kept sagging. Simply Wall Street ran a story yesterday headlined, “The Market Doesn’t Like What It Sees From Moderna, Inc.’s Revenues Yet As Shares Tumble 28%.” Uh oh.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/the-market-doesnt-like-what-it-sees-from-moderna-incs-nasdaq?

Last week, Moderna depressed investors after appearing in the UK Daily Telegraph under the headline, “Moderna under fire after children offered cash to test Covid vaccine.” The sub-headline added, “Company targeted 12 to 18 year-olds through WhatsApp with payments of £1,500.” That’s about $2,000.

https://www.telegraph.co.uk/news/2024/10/02/moderna-offered-children-cash-test-covid-vaccine/?

They used to convince people to take the jabs for a free donut. Now they’re having to offer thousands of dollars. It’s not a good sign for demand, which at this point could be reasonably compared to the demand for spicy cayenne pepper enemas or radical bee sting therapy. Ouch!

The larger significance is what this says about the market’s response to mRNA therapies in general. Remember, Moderna’s unexciting drug pipeline is all mRNA. Until very recently, mRNA was the hottest thing going. They were going to cure cancer with individualized mRNA shots.

But now, nobody wants their stupid shots, not even people fighting cancer. Instead, all the cancer treatment excitement revolves around taking ivermectin, even though —or maybe because— the FDA panned the safe and effective drug as a horse dewormer.

Progress.